[Expression of PDCD5 in tissues of normal cervix, CIN I-III and cervical cancer].
[Expression of PDCD5 in tissues of normal cervix, CIN I-III and cervical cancer].
复制标题
DOI：
--
复制
发表时间：
2004-08
影响因子：
--
通讯作者：
Zhaohui Liu;Dai Zhang;Ke-min Li;Q. Liao
中科院分区：
文献类型：
--
作者：
Zhaohui Liu;Dai Zhang;Ke-min Li;Q. Liao
目的探讨PDCD5在正常宫颈组织、CIN - iii、宫颈癌组织中的表达，探讨PDCD5与宫颈癌的关系。方法采用间接免疫组化技术对18例正常宫颈、19例CIN、18例CIN、20例CIN和18例宫颈癌组织进行定性。通过显微镜观察和计算机成像技术分析，观察PDCD5蛋白的阳性表达率和表达强度。结果采用单因素方差分析。结果免疫组化染色结果显示，宫颈正常组织和CIN组强阳性细胞比例明显高于CIN组、CIN组和宫颈癌组。在免疫组化染色的整体情况下，PDCD5的表达在宫颈不典型上皮的进展过程中下调，而在CIN中表达上调。正常子宫颈、CIN I-III、宫颈癌的od值分别为0.322、0.366、0.287、0.252、0.206。各组用药强度有明显差异。结论PDCD5在CIN中表达上调，在CIN、CIN和宫颈癌中表达下调。提示PDCD5是宫颈癌发生过程中重要的凋亡调节因子。
OBJECTIVE To investigate the expression of PDCD5 in tissues of normal cervix, CIN I-III, cervical cancer and explore the relationship between PDCD5 and cervical cancer. METHODS After we defined the most fitful condition, tissues from 18 cases of normal cervix, 19 of CIN I, 18 of CIN II, 20 of CIN III and 18 of cervical cancer were defined by indirect immunohistochemical technique. Positive expression rates and intensity of PDCD5 protein were investigated by observing under microscope and analyzing with computer imaging technique. The results were analyzed with one-way anova. RESULTS The results of immunohistochemical staining showed that the percentage of strong positive cells in normal cervical tissue and CIN I were significant higher than those of CIN II, CIN III and cervical cancer. On the whole of the condition of immunohistochemical staining, the expressions of PDCD5 were downregulated along the progression of cervical atypical epithelia, but that in CIN I was upregulated. The ODs of normal cervix,CIN I-III,cervical cancer were 0.322, 0.366, 0.287, 0.252, and 0.206 respectively. The intensity of each group showed obvious differences. CONCLUSION We found that the expression of PDCD5 was upregulated in CIN I and downregulated in CIN II, CIN III and cervical cancer. It suggests that PDCD5 is an important apoptosis regulating factor in the occurrence of cervical cancer.